Clinical Trials Browser

Phase 1 × Completed × bosutinib × Clear all

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03023319 2022-06-14

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Phase 1 Completed

GenitourinaryGynecologicOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Mesothelioma, Ovarian Neoplasms, Thymoma, Thymus Neoplasms

NCT02058277 2014-06-24

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00195260 2013-02-11

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Phase 1 Completed

151 enrolled 21 charts

Neoplasms

NCT01374139 2011-11-30

Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01001936 2009-10-27

Study Evaluating SKI-606 in Subject With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00759837 2009-07-16

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

Phase 1 Completed

BreastMyeloidOther hematologic neoplasm

Breast Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00777530 2008-10-23

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Phase 1 Completed

BreastOther hematologic neoplasm

Breast Neoplasms, Leukemia, Neoplasms